SC allowed classification of Odomos under HSN 38089191 to stand, holding that market identity and consumer understanding ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

Chronic viral infections, including HPV, HIV, viral hepatitis, and herpesviruses, affect over a billion people worldwide and are responsible for millions of ...

GLP-1 agonists have become the dominant spend catalyst, with class spending ~$132B and growth contribution approaching ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and ...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...

Recently, a proposed amendment announced by the Tshiamiso Trust — set up to disburse compensation — now threatens to shut out ...

Four weeks after several hundred Grand Erie students were suspended by the local health unit over missing immunization ...

RD Research has helped to find a major breakthrough that could change the way conditions like motor neurone disease and ALS are understood ...

BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing GLIX1 as its lead asset, targeting DNA damage response in glioblastoma and other ...

The dismantling of public health through NIH funding cuts, CDC censorship and Medicaid rollbacks is a deliberate attack on ...